Cleveland BioLabs Company Profile (NASDAQ:CBLI)

About Cleveland BioLabs (NASDAQ:CBLI)

Cleveland BioLabs logoCleveland BioLabs, Inc. (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CBLI
  • CUSIP: N/A
  • Web: www.cbiolabs.com
Capitalization:
  • Market Cap: $34.29 million
  • Outstanding Shares: 11,279,000
Average Prices:
  • 50 Day Moving Avg: $2.78
  • 200 Day Moving Avg: $2.82
  • 52 Week Range: $1.22 - $5.55
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $2.91 million
  • Price / Sales: 12.60
  • Book Value: $0.41 per share
  • Price / Book: 7.93
Profitability:
  • EBIDTA: ($5,710,000.00)
  • Net Margins: -253.09%
  • Return on Equity: -61.18%
  • Return on Assets: -49.90%
Debt:
  • Current Ratio: 5.18%
  • Quick Ratio: 5.18%
Misc:
  • Average Volume: 63,584 shs.
  • Beta: 0.2
  • Short Ratio: 2.13
 

Frequently Asked Questions for Cleveland BioLabs (NASDAQ:CBLI)

What is Cleveland BioLabs' stock symbol?

Cleveland BioLabs trades on the NASDAQ under the ticker symbol "CBLI."

How were Cleveland BioLabs' earnings last quarter?

Cleveland BioLabs, Inc. (NASDAQ:CBLI) posted its earnings results on Monday, August, 14th. The company reported ($0.50) EPS for the quarter. The company earned $0.21 million during the quarter. Cleveland BioLabs had a negative return on equity of 61.18% and a negative net margin of 253.09%. View Cleveland BioLabs' Earnings History.

Who are some of Cleveland BioLabs' key competitors?

Who are Cleveland BioLabs' key executives?

Cleveland BioLabs' management team includes the folowing people:

  • Langdon L. Miller M.D., President
  • Yakov N. Kogan Ph.D., Chief Executive Officer, Principal Financial Officer
  • Andrei V. Gudkov Ph.D., Chief Scientific Officer
  • Alexander Andryushechkin, Independent Director
  • Anna Evdokimova, Independent Director
  • Alexey Nechaev, Independent Director
  • Ivan Persiyanov, Independent Director
  • Randy S. Saluck J.D., Independent Director

Who owns Cleveland BioLabs stock?

Cleveland BioLabs' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (1.51%) and Virtu KCG Holdings LLC (0.46%). View Institutional Ownership Trends for Cleveland BioLabs.

Who bought Cleveland BioLabs stock? Who is buying Cleveland BioLabs stock?

Cleveland BioLabs' stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc. and Virtu KCG Holdings LLC. View Insider Buying and Selling for Cleveland BioLabs.

How do I buy Cleveland BioLabs stock?

Shares of Cleveland BioLabs can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cleveland BioLabs' stock price today?

One share of Cleveland BioLabs stock can currently be purchased for approximately $3.25.


MarketBeat Community Rating for Cleveland BioLabs (NASDAQ CBLI)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  41 (Vote Outperform)
Underperform Votes:  28 (Vote Underperform)
Total Votes:  69
MarketBeat's community ratings are surveys of what our community members think about Cleveland BioLabs and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Cleveland BioLabs (NASDAQ:CBLI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Cleveland BioLabs (NASDAQ:CBLI)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Cleveland BioLabs (NASDAQ:CBLI)
Earnings by Quarter for Cleveland BioLabs (NASDAQ:CBLI)
Earnings History by Quarter for Cleveland BioLabs (NASDAQ CBLI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/14/2017Q2 2017($0.50)$0.21 millionViewN/AView Earnings Details
5/15/2017Q1 2017($0.15)$0.58 millionViewN/AView Earnings Details
2/22/2017Q4 2016($0.11)$0.99 millionViewN/AView Earnings Details
8/15/2016Q2($0.17)$0.58 millionViewN/AView Earnings Details
5/16/2016Q116($0.06)$0.81 millionViewN/AView Earnings Details
11/5/2015Q315$0.31$415.00 million$0.50 millionViewN/AView Earnings Details
8/12/2015Q215($0.72)$562.10 million$329.90 millionViewListenView Earnings Details
5/6/2015Q115($1.14)$1.33 million$0.61 millionViewN/AView Earnings Details
2/24/2015Q114($1.02)$3.87 million$1.39 millionViewN/AView Earnings Details
3/11/2014Q413($0.12)($0.01)$1.74 million$3.87 millionViewN/AView Earnings Details
11/6/2013Q313($0.14)($0.09)$1.61 million$1.60 millionViewN/AView Earnings Details
8/13/2013Q2 2013($0.16)($0.07)$1.48 million$1.60 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.17)($0.22)$1.73 million$1.37 millionViewN/AView Earnings Details
11/8/2012Q312($0.02)($0.30)$23.87 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cleveland BioLabs (NASDAQ:CBLI)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Cleveland BioLabs (NASDAQ:CBLI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Cleveland BioLabs (NASDAQ:CBLI)
Insider Ownership Percentage: 2.44%
Institutional Ownership Percentage: 4.58%
Insider Trades by Quarter for Cleveland BioLabs (NASDAQ:CBLI)
Insider Trades by Quarter for Cleveland BioLabs (NASDAQ:CBLI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/25/2015Randy S SaluckDirectorBuy1,891$3.42$6,467.22View SEC Filing  
5/21/2013Paul E DicorletoDirectorBuy6,210$1.61$9,998.10View SEC Filing  
5/17/2013Randy S SaluckDirectorBuy3,500$1.60$5,600.00View SEC Filing  
3/15/2013James AntalDirectorBuy3,700$1.56$5,772.00View SEC Filing  
9/21/2012James AntalDirectorBuy2,316$2.60$6,021.60View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Cleveland BioLabs (NASDAQ:CBLI)
Latest Headlines for Cleveland BioLabs (NASDAQ:CBLI)
Source:
DateHeadline
finance.yahoo.com logoETFs with exposure to Cleveland BioLabs, Inc. : September 19, 2017
finance.yahoo.com - September 19 at 10:01 PM
finance.yahoo.com logoCleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017
finance.yahoo.com - September 18 at 5:17 PM
americanbankingnews.com logoContrasting Cleveland BioLabs (CBLI) and Asterias Biotherapeutics (AST)
www.americanbankingnews.com - September 17 at 2:31 AM
finance.yahoo.com logoWhat You Must Know About Cleveland BioLabs Inc’s (CBLI) Risks
finance.yahoo.com - September 11 at 5:34 PM
americanbankingnews.com logoCleveland BioLabs, Inc. (CBLI) Posts Earnings Results
www.americanbankingnews.com - August 15 at 9:41 AM
finance.yahoo.com logoCleveland Biolabs Countermeasure for Acute Radiation Syndrome, Pipeline Review, and Market Potential
finance.yahoo.com - August 11 at 5:26 PM
finance.yahoo.com logoETFs with exposure to Cleveland BioLabs, Inc. : August 4, 2017
finance.yahoo.com - August 4 at 10:18 PM
finance.yahoo.com logoETFs with exposure to Cleveland BioLabs, Inc. : July 12, 2017
finance.yahoo.com - July 12 at 5:35 PM
americanbankingnews.com logoValuEngine Downgrades Cleveland BioLabs, Inc. (CBLI) to Sell
www.americanbankingnews.com - June 29 at 11:08 PM
finance.yahoo.com logoETFs with exposure to Cleveland BioLabs, Inc. : June 26, 2017
finance.yahoo.com - June 26 at 4:51 PM
finance.yahoo.com logoETFs with exposure to Cleveland BioLabs, Inc. : June 16, 2017
finance.yahoo.com - June 16 at 4:56 PM
americanbankingnews.com logoShort Interest in Cleveland BioLabs, Inc. (CBLI) Decreases By 50.5%
www.americanbankingnews.com - June 13 at 7:04 AM
finance.yahoo.com logoETFs with exposure to Cleveland BioLabs, Inc. : June 5, 2017
finance.yahoo.com - June 5 at 4:07 PM
finance.yahoo.com logoCleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 2 at 5:39 PM
americanbankingnews.com logoShort Interest in Cleveland BioLabs, Inc. (CBLI) Drops By 30.7%
www.americanbankingnews.com - May 29 at 7:14 AM
feeds.benzinga.com logoCleveland BioLabs Reports First Quarter 2017 Financial Results and Development Progress
feeds.benzinga.com - May 15 at 8:01 AM
americanbankingnews.com logoCleveland BioLabs (CBLI) Earning Critical Media Coverage, Report Shows
www.americanbankingnews.com - April 21 at 7:49 AM
finance.yahoo.com logoGovernments Looking at Cleveland Biolabs Radiation Countermeasure
finance.yahoo.com - April 20 at 11:08 AM
finanznachrichten.de logoGainers & Losers Of Apr.19: SNGX, IMGN, CBLI, SSH, AKTX...
www.finanznachrichten.de - April 19 at 11:03 PM
finance.yahoo.com logoETFs with exposure to Cleveland BioLabs, Inc. : April 19, 2017
finance.yahoo.com - April 19 at 6:02 PM
investorplace.com logoCleveland BioLabs, Inc. (CBLI) Stock Tacks On Another 40%-Plus
investorplace.com - April 19 at 3:33 PM
streetinsider.com logoCleveland Biolabs (CBLI) to Begin In Vivo Bio-Comparability Study Following FDA Review
www.streetinsider.com - April 19 at 1:01 PM
americanbankingnews.com logoCleveland BioLabs (CBLI) Earning Somewhat Positive Media Coverage, Analysis Finds
www.americanbankingnews.com - April 18 at 1:38 PM
finance.yahoo.com logoCleveland BioLabs Announces European Medicines Agency Positive Opinion Regarding the Entolimod Pediatric Investigation Plan
finance.yahoo.com - April 17 at 12:17 PM
finance.yahoo.com logoCleveland BioLabs Announces Commencement of In Vivo Biocomparability Study
finance.yahoo.com - April 17 at 12:17 PM
finance.yahoo.com logoETFs with exposure to Cleveland BioLabs, Inc. : April 7, 2017
finance.yahoo.com - April 7 at 9:11 PM
biz.yahoo.com logoCLEVELAND BIOLABS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
biz.yahoo.com - February 22 at 9:21 PM
finance.yahoo.com logoCleveland BioLabs Reports 2016 Financial Results and Development Progress
finance.yahoo.com - February 22 at 4:20 PM
finance.yahoo.com logoCLEVELAND BIOLABS INC Financials
finance.yahoo.com - November 20 at 8:11 AM
streetinsider.com logoCleveland Biolabs (CBLI) Announces $1.1M JWMRP Contract Modification with U.S. DoD
www.streetinsider.com - October 12 at 8:37 AM
reuters.com logoBRIEF-Cleveland BioLabs announces a $1.1 mln cost realignment with Department of Defense
www.reuters.com - October 11 at 4:13 PM
biz.yahoo.com logoCLEVELAND BIOLABS INC Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - July 22 at 4:22 PM
biz.yahoo.com logoCLEVELAND BIOLABS INC Files SEC form 8-K/A, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta
biz.yahoo.com - July 21 at 6:05 AM
biz.yahoo.com logoCLEVELAND BIOLABS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Stand
biz.yahoo.com - July 12 at 4:25 PM
bizjournals.com logo22nd Century to begin cannabis research at new medical campus labs
www.bizjournals.com - May 12 at 2:40 PM
biz.yahoo.com logoCLEVELAND BIOLABS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibit
biz.yahoo.com - May 6 at 5:55 PM
biz.yahoo.com logoCLEVELAND BIOLABS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
biz.yahoo.com - April 15 at 3:05 PM
rttnews.com logoGLPG Awaits SAPHIRA Data, VTAE Vaults, CBLI Hits A Snag
www.rttnews.com - March 17 at 2:04 AM
biz.yahoo.com logoCLEVELAND BIOLABS INC Files SEC form 8-K, Other Events
biz.yahoo.com - March 16 at 2:50 PM
finance.yahoo.com logoCleveland BioLabs Provides Update on Pre-EUA Review of Entolimod as Radiation Countermeasure
finance.yahoo.com - March 16 at 2:00 PM
investorplace.com logoHottest Services Stocks Now – CAI NEWT INST MOBL
investorplace.com - March 8 at 11:42 AM
biz.yahoo.com logoCLEVELAND BIOLABS INC Files SEC form 10-K, Annual Report
biz.yahoo.com - February 23 at 5:04 PM
biz.yahoo.com logoCLEVELAND BIOLABS INC Files SEC form 8-K, Results of Operations and Financial Condition
biz.yahoo.com - February 22 at 10:35 AM
finance.yahoo.com logoCleveland BioLabs Reports 2015 Financial Results and Development Progress
finance.yahoo.com - February 22 at 7:30 AM
biz.yahoo.com logoCleveland BioLabs, Inc. (CBLI)
biz.yahoo.com - February 18 at 6:31 PM
investorplace.com logoHottest Services Stocks Now – ADUS SREV EBIX CBLI
investorplace.com - February 9 at 10:47 AM
streetinsider.com logoCleveland Biolabs (CBLI) Says Entolimod Shown to Suppress Metastasis and Induce Immunity by Stimulating NK-Dendritic-CD8+ T cell Axis
www.streetinsider.com - February 9 at 10:47 AM
finance.yahoo.com logoEntolimod Shown to Suppress Metastasis and Induce Immunity by Stimulating NK-Dendritic-CD8+ T cell Axis in Studies by Cleveland BioLabs and Roswell Park Cancer Institute
finance.yahoo.com - February 9 at 7:30 AM
finance.yahoo.com logoCleveland BioLabs Announces Start of Colorectal Cancer Study of Entolimod in Russian Federation
finance.yahoo.com - February 2 at 8:00 AM
finance.yahoo.com logoCleveland BioLabs Gets Orphan Status for Entolimod in EU
finance.yahoo.com - January 22 at 3:25 PM

Social

Chart

Cleveland BioLabs (CBLI) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by MarketBeat.com Staff